AUTHOR INDEX

Volume 24, 1992

Abe, M., 959
Abe, Y., 806
Abitbol, A. A., 777, 795
Abuchaibe, O., 729
Acord, P., 583
Aimard, L., 79
Albright, N. W., 307
Albuisson, E., 469
Allen, D., 633
Allen, K., 633
Alul, I. H., 315
Alvarez-Cienfuegos, J., 729
Ang, K. K., 287, 693
Anolik, S. L., 543
Anscher, M. S., 435, 489, 633
Aristei, C., 301
Aristu, J. J., 729
Armbruster, J. S., 815, 857
Armour, E. P., 965
Armstrong, J. G., 43, 747
Asbell, S. O., 441
Astrahan, M. A., 247
Attix, F. H., 167
Avitable, M., 451
Azinovic, I., 729
Aziz, H., 451

Baba, N., 959
Bagshaw, M. A., 403, 415
Baillet, F., 469
Baris, G., 551
Barish, R. J., 805
Barnett, T. A., 261
Barraclough, B., 253
Beck-Bornholdt, H.-P., 806
Becker, G., 781
Bell, J., 389
Ben-Yosef, R., 261
Bernard, J. L., 79
Besa, P., 73
Bhat, S. B., 3
Bigner, D. D., 103
Bilou, A. M., 253
Binns, P. J., 975
Bleehen, N. M., 675
Blitzer, P. H., 3
Boccieri, M. G., 11
Bolzicco, G., 11
Bonnet, J., 479
Bonneterre, J., 187
Bonomi, P., 17
Boothman, D. A., 939, 949
Bortfeld, T., 781
Bosch, C., 253
Bosker, F. J., 721
Bouffet, E., 79
Bouma, J., 359
Boyages, J., 253
Brady, L. W., 815
Braunschweiger, P. G., 795
Bresch, J. P., 903
Britten, R. A., 527
Brizel, D. M., 103
Brock, W. A., 287, 511
Brockman, W. P., 187
Brown, J. M., 279, 737
Brunat-Mentigny, M., 79
Buchler, D. A., 335, 349
Buchsbaum, D. J., 329
Budach, V., 119
Budach, W., 119
Bundy, B. N., 389
Burrows, H. L., 939, 949

Cairncross, J. G., 55, 803
Calitchi, E., 59
Calvo, F. A., 729
Cardenes, H., 145
Carrie, C., 79
Carton, M., 79
Cassady, J. R., 657, 807
Castro, J. R., 755
Cetas, T., 657, 807
Cha, S. D., 229
Chadha, T. T., 3
Chandrahasa, T., 3
Checcaglini, F., 301
Chiang, C. S., 929
Chin, L. M., 789
Choux, M., 79
Chu, J. C. H., 559
Cogen, P. H., 599
Coia, L. R., 891, 903, 983
Collier, J. M., 755
Constine, L. S., 651, 881
Corn, B. W., 223
Corry, P. M., 965
Cox, C. A., 415
Cox, R. S., 261, 403, 415
Crabtree, W. N., 139
Crawford, J., 633
Crommelin, M. A., 241
Cummings, B. J., 188, 861, 883
Curran, Jr., W. J., 25, 31, 37
Curtin, J. P., 747

Daftari, I., 755
Daly, N. J., 479, 845
Dalziel, W. C., 519
Davelaar, J., 819
de Neve, W., 241
De Ruysscher, D., 133
Delannes, M., 479
Delclos, L., 73
Deore, S. M., 217
Deutsch, M., 633
Devineni, V. R., 145
DeWerd, L. A., 167
Diamond, J. J., 903
Dillehay, L. E., 111, 699
Dinshaw, K. A., 217
Dische, S., 87
Djordjevic, B., 511
Dodge, R., 633
Doggett, R. L. S., 441
Donaldson, S. S., 881
Donnarieix, D., 469
Dorie, M. J., 295
Dosani, R. A., 3
Dosoretz, D. E., 3
Douchez, J., 469, 479
Dougherty, M. J., 25
Dubben, H.-H., 806
Dunscombe, P., 179
Dusenbery, K. E., 315

Edwards, C. L., 73
Edwards, J. A., 111
Edwards, M. S. B., 599
Eifel, P. J., 211, 381
El-Mahdi, A. M., 409, 431, 569
Emami, B., 145
Epstein, B. E., 485
Escude, L., 729
Evans, J., 279, 737
Evans, R. G. B., 825, 863, 867
Evans, R. G., 519

Faber, L. P., 17
Fagundes, H., 197, 387
Fass, D., 43
Feldmann, H.-J., 119
Fiedler, J. A., 795
Fijuth, J., 59
Finkelstein, J., 93
Fisher, B. J., 55
Fitzgerald, T., 229
Flynn, D. F., 909
Forio, I., 49
Fossati-Bellani, F., 761
Fowler, J. F., 188, 335, 349, 574
Fox, K., 177
Fraas, B. A., 767
Franchin, G., 11, 573
Franken, N. A. P., 721
Frappaz, D., 79
Friedman, H. S., 103
Fuks, Z., 43, 183, 377
Fukunaga, N., 949

Gademann, G., 781
Gale, M., 17
Gandola, L., 761
Gaspar, L. E., 55, 803
Gasparini, M., 761
Gauwitz, M. D., 153
Gaydica, E., 633
Gazda, M. J., 693
Geara, F. B., 287
Gebski, V. J., 253
Gehring, M. A., 619
Gentet, J. C., 79
Gerard, J.-P., 845, 469
Gerbaulet, A., 469
Gianni, M. C., 761
Giralt, J., 49
Giraud, B., 469
Gobitti, C., 11, 573
Goetsch, S. J., 167
Gonzalez-Arias, S., 777
Gratzl, O., 627
Grdina, D., 687
Green, J. A., 527
Greven, K. M., 223
Griffin, T. W., 901
Griffith, O. W., 103
Grigsby, P. W., 197, 321
Guthkelch, N., 657
Gutin, P. H., 583, 593

Haddad, E., 59
Haffty, B. G., 181
Hall, E. J., 847
Hallahan, D. E., 565, 687
Halperin, E. C., 55, 103
Ham, B., 583, 593
Hamilton, A., 657
Hanks, G. E., 223, 485, 571, 815, 891, 913, 983
Hannan, S. E., 3
Hareyama, M., 235
Harrison, L., 43, 747
Hazle, J. D., 559
Heeren, G., 813, 819
Heidorn, D. B., 329
Heller, P. B., 389
Hendrickson, F. R., 17
Herbert, S. H., 25, 31
Hernandez, J. L., 729
Hilaris, B. S., 877
Hodge, L., 369
Hoekstra, C. J. M., 555
Holland, E. J., 315
Holsti, L. R., 643
Honore, G., 103
Hoogenraad, W. J., 497
Hornback, N. B., 139
Houdek, P. V., 777, 795
Hough, J. H., 975
Hübener, K. H., 187
Hughes, E., 25, 37
Hünig, R., 627
Hunt, M. A., 485
Hunter, R. E., 229
Huq, M. S., 171
Hussain, F., 451
Hussey, D. H., 909

Jansma, J., 359
Joannard, A., 79
Johnstone, A. K., 681

Kaanders, J. H. A. M., 497
Kagami, Y., 235
Kajanti, M., 643
Kallman, R. F., 295
Kaplan, E., 17
Kaplan, I., 403, 415
Kapp, D. S., 261, 573
Karasek, K., 651
Katin, M. J., 3
Kavadi, V. S., 211
Kavanaugh, B., 633
Keller, J. W., 441
Keller, S., 25
Kennedy, P., 559
Kersey, J. H., 705
Khan, F. M., 315, 853
Khattab, T. Y., 161
Kimler, B. F., 519
Kinsella, T. J., 335, 349, 619
Kittelson, J., 657
Kittle, C. F., 17
Kivisaari, L., 643
Kleiboer, B. J., 505
Knopf, K., 755
Komaki, R., 185
Kovacs, M. S., 279
Krall, J., 441
Kramer, S., 611
Krawczyk, A., 65
Krawczyk, J., 65
Kris, M., 43
Kuban, D. A., 409, 431, 569
Kubsad, S. S., 619
Kucik, N., 145
Kufe, D. W., 565
Kuske, R. R., 145

Lai, P. P., 423, 713
Lamb, S. A., 583, 593
Lamborn, K. R., 583
Lanciano, R. M., 223
Landmann, C., 627
Landuyt, W., 133
Lange, C. S., 511
Langholz, B., 247
Langlands, A. O., 253
Langmuir, V. K., 127
Lapras, C., 79
Larson, D. A., 307, 583, 593, 599, 885, 897
Latini, P., 301
Lavey, R. S., 681
La Vigne, M. L., 767
LeBer, D. V., 55
Le Bourgeois, J.-P., 59
Lee, M. S., 17
Leer, J. W. H., 813, 819, 837
Leibel, S., 43, 377, 811
Leopold, K. A., 489, 633
Le Péchoux, C., 59
Levin, A. B., 619
Levin, V. A., 599
Levitt, S. H., 315
Lewin, A. A., 777, 795
Leybovich, L., 145
Liggett, P. E., 247
Lochrin, C. A., 87
Lockett, M. A., 197, 423
Loeffler, J. S., 885
Lombardi, F., 761
Lorenz, W. J., 781
Lowrey, G. C., 205
Lulu, B., 657
Luxton, G., 247
Lybeert, M. L. M., 241

Maasilta, P., 643
Macchia, R., 451
Macdonald, D. R., 55
Mackey, M. A., 543
Mackie, T. R., 619
Maezawa, H., 533
Mak, A. C. A., 555
Malavaud, B., 479
Malec, M., 583, 593
Manabe, T., 959
Mäntylä, M., 643
Maranzano, E., 301
Marcial-Vega, V., 777
Margolese-Malin, L., 369
Markoe, A. M., 795
Marks, J. E., 815, 857, 871, 875, 987
Marks, L. B., 435
Martijn, H., 241
Martin, M., 59
Martinez, A., 965
Martinez, R., 729
Mason, K. A., 929
Mattson, K., 643
Mauch, P., 789
Mazeron, J.-J., 59, 469
McBride, W. H., 681, 929
McKenna, W. G., 25, 37
McNally, N. J., 87
McShan, D. L., 767
Mehta, M. P., 619
Meli, J. A., 171
Mella, O., 669
Mendenhall, W. M., 205
Mendonca, H. L., 127
Mestas, G., 3
Metke, M. P., 3
Meyers, M., 949
Mijnheer, B. J., 789
Mildenberger, M., 145
Million, R. R., 205
Minatel, E., 11, 573
Minne, J. F., 187
Mohiuddin, M., 463, 921
Moldofsky, P. J., 31
Monfardini, S., 11
Montana, G., 633
Mori, M., 737
Mulholland, S. G., 463
Mychalczak, B., 747
Myerson, R. J., 145

Narimatsu, N., 235
Nascimben, O., 11
Nesbit, M., 705
Nguyen, T. D., 469
Nishio, M., 235
Noordijk, E. M., 837
Nordenskjold, K., 841

Obbens, E., 657
Obcemea, C. H., 789
Okagaki, T., 389
Oleson, J. R., 381, 489
Olive, T., 49
Order, S. E., 895
Ortega, J. J., 49
Orton, C. G., 387
Ota, D. M., 73
Overgaard, J., 813, 819
Owen, J., 913, 983
Owens, J. K., 939

Paliwal, B., 335, 349
Panders, A. K., 359
Panizza, B. M., 301
Pardo, F., 729
Paris, K. G., 145
Parker, R. G., 815
Pastyr, O., 781
Perez, C. A., 145, 197, 321, 387, 423, 441
Pernot, M., 469
Perrucci, E., 301
Peters, L. J., 287, 693
Peters, T., 913
Petrovich, Z., 247
Petti, P. L., 755
Philip, T., 79
Phillips, T. L., 307, 583, 593, 755, 897
Philput, C. B., 431
Piedbois, P., 59
Pierquin, B., 59
Pilepich, M. V., 441
Pisciotta, V., 795
Pizzi, G., 11
Prados, M. D., 583, 593, 599
Prestidge, B. R., 403
Pyrhönen, S., 643

Ramsay, J., 675
Ramsay, N. K. C., 705
Rashid, M., 3
Rautonen, J., 643
Raybaud, C., 79
Reale, F., 229
Reddy, S., 17
Regine, W. F., 611, 921
Reisinger, S. A., 223, 463
Reynart, I. W. C., 721
Ribot, J. G., 241
Ricci, S., 301
Rice, R. K., 789
Rich, T. A., 73
Roach, III, M., 441
Roberson, P. L., 329
Roberts, J., 389
Roche, H., 79
Rose, P. G., 229
Rosenman, J., 369
Rosenstein, M., 43
Rosenthal, S. A., 25, 37
Rosier, R., 651
Rossman, K., 657
Roszinski, S., 669
Roti Roti, J. L., 543
Rotman, M., 441, 451
Rottoli, L., 761
Rozan, R., 469
Rozental, J. M., 619
Rubenstein, J. H., 3
Rubin, P., 1, 93, 195, 401, 811
Ruifrok, A. C. C., 505
Russ, H., 441
Russell, A. H., 187

Sack, H., 119
Saito, A., 235
Sakaguchi, M., 959
Sakurai, T., 235
Salenius, S., 3, 369
Salminen, U.-S., 643
Salvador, L., 49
Samulski, T. V., 489
Sandison, G. A., 139
Sandler, H. M., 25, 37, 767
Sasai, K., 959
Sauer, R., 187
Saunders, M. I., 87
Sause, W. T., 441
Schaake-Koning, C., 551
Schad, L., 781
Scharfen, C. O., 583
Schea, R., 939, 949
Schellhammer, P., 409
Scher, H., 43
Schlegel, W., 781
Schoenthaler, R., 307
Schold, Jr., S. C., 55
Schultheiss, T. E., 693
Schultz, D. J., 223
Schwade, J. G., 777, 795
Serago, C. F., 777, 795
's-Gravenmade, E. J., 359
Shaeffer, J., 431
Shahabi, S., 349
Shank, B., 43, 889
Shapiro, D., 93
Shapiro, W., 657
Shen, R.-N., 139
Shetter, A., 657
Shibamoto, Y., 959
Shidnia, H., 139
Shipley, W., 441
Shrieve, D. C., 599
Shrivastava, S. K., 217
Shultz, G. L., 805
Shultz, K., 805
Siddon, R. L., 789
Siegel, A. D., 3
Sklar, M. D., 795
Smalley, S. R., 519
Smith, A. R., 851
Smith, L. M., 737
Sneed, P. K., 583, 593, 599
Soffen, E. M., 485
Solin, L. J., 31
Sommer, K., 187
Song, C. W., 705
Sontag, M. R., 103
Stafford, P. M., 25, 37, 223
Staub, E. W., 633
Stea, B., 657, 807

Stehman, F. B., 389
Stenfert Kroese, M. C., 555
Stephens, L. C., 693
Stevens, C., 907
Stitt, J. A., 335, 349, 574
Stock, R. G., 747
Straube, W., 145
Strickfaden, S., 939
Strootman, E., 721
Stuschke, M., 119
Su, F.-M., 127
Sukhatme, V. P., 565
Supe, S. J., 217
Sutedja, G., 551
Svoboda, V. H., 65

Tak, W. K., 229
Takahashi, M., 959
Tammilehto, L., 643
Tangco, E., 729
Tarbell, N. J., 789
Taylor, IV, S. G., 17
Taylor, J. M. G., 681
Taylor, Y. C., 713
Tegeler, J. A., 431
te Loo, H. J., 555
Ten Haken, R. K., 329, 767
Tepper, J. E., 369
Thomadsen, B. R., 167, 335, 349, 574
Thomas, G., 389
Thornton, Jr., A. F., 767
Torretta, A., 11
Tron, P., 79
Trovó, M. G., 11, 573

Uckun, F. M., 705
Uhl, V., 755
Urano, M., 533, 806

van Daal, W. A. J., 497
Vandeputte, M., 133
Vanderheyden, J.-L., 127
van der Kogel, A. J., 497, 505
van der Laarse, A., 721
van der Schueren, E., 133
van Ravels, F. J. M., 721
van Slooten, F. H. S., 555
van't Riet, A., 555
van Zandwijk, N., 551
Varia, M., 369, 389
Venkataramanan, N., 171
Verges, R., 49
Vermey, A., 359
Veronesi, A., 11
Virudachalam, S., 687
Vissink, A., 359
Viswanathan, P. S., 217

Waer, M., 133
Wagner, Th., 669
Wang, M., 939
Wang, Z., 965
Wara, W. M., 307, 583, 593, 599
Ward, R., 675
Warenius, H. M., 527
Warren, W., 17
Weaver, K. A., 583
Weichselbaum, R. R., 183, 565, 687
Weiss, C., 669
Wharton, J. T., 73
Wiedemann, G., 669
Wiegel, T., 187
Wike, J. L., 287
Williams, J. A., 111
Williams, J. R., 699
Williamson, J. F., 321
Wilson, C. B., 307, 593
Wilson, G. D., 87
Wilson, J. F., 877, 903
Withers, H. R., 929
Wolfe, W., 633
Wondergem, J., 721
Wong, C. S., 188
Wong, K.-H., 533
Wu, B., 139
Wu, X., 795

Yanke, B. R., 767
Young, P., 139
Ypma, A. F. G. V. M., 555

Zagars, G. K., 153
Zaghoul, M. S., 161
Zanelli, D. J., 11
Zanelli, G. D., 573
Zhang, X., 713
Zhang, Y.-G., 699

SUBJECT INDEX

Volume 24, 1992

A

Accelerated fractionation, 497
Acquired chemoresistance, 527
Acute morbidity, 485
Adjuvant
  Radiation therapy, 463
  Therapy, 921
Adrenergic receptor density, 721
Afterloaders
  High-dose rate, 167, 335
  Remote, 321
Age, 505
Algorithm, 795
ALL, 49
α-adrenergic receptor, 721
Alveolar macrophage, 93
Anaplastic astrocytoma, 593
Antibodies, 329
^{131}Iodine monoclonal, 329
  Monoclonal, 127
  Radiolabeled, 329
Apoptosis, 693
Asbestos exposure, 643
Assay
  MTT, 675
  Predictive, 279
Ataxia telangiectasia, 949

B

Backscatter from high Z, 171
β-adrenergic receptor, 721
β-irradiation, 315
Biopsy, 409
  Post-treatment, 403
Blacks and prostate cancer, 441
Bladder
  Cancer, 469
  Carcinoma, 463
Bleomycin, 295
Bloom's syndrome, 949
Bone tumors, 755
Boost field, 55
Bowel toxicity, 463
Brachytherapy, 167, 321, 335, 349, 469, 551, 593, 747, 965
  High dose-rate, 795
  Interstitial, 479, 583
  Intracavitary, 235
  192, 59
Brain metastases, 619
Brain
  Neoplasm(s), 93, 583, 767
  Pediatric tumors, 599
  Tumors, 79
Brainstem glioma, 599
Breast cancer, 65, 301
  Recurrent, 261
Bromodeoxyuridine, 87
Buthionine sulfoximine, 103

C

Camptothecin, 939
Cancer(s)
  Bladder, 469
  Breast, 65, 301
  Cervical, 211
  Cervix, 217
  Colon, 329
  Endometrial, 223
  Esophageal, 633
  Gastric, 729
  Head and neck, 59, 359
  Incidental prostate, 415
  Laryngeal, 497
  Non-small cell lung, 551
  Ovarian, 161
  Prostate, 403, 423, 435, 485, 489
  Recurrent breast, 261
  Second, 913
  Survival and race, 441
  Therapy, 329
Carcinoma(s)
  Bladder, 463
  Cervical, 335
  Endometrial, 229
  Penile, 479
  Pituitary, 307
  Prostate, 431
  Prostatic, 451
  Rectal, 241
  Squamous cell, 59
  Thoracic esophageal, 235
  Vulva, 389
Cardiac injury, 913
cDDp, 11
Cell(s)
  Cycle regulation, 687
  Epithelial, 533
  Human tumor, 119
  Kinetics, 87, 713
  Non-small, 3
  Radioresistant human melanoma (U1-Mel), 939
  Stem, 119
Cellular
  Immunity, 133
  Radiosensitivity, 699
Cervical
  Cancer, 211
  Carcinoma, 335, 349
Cervix, 197
  Cancer, 217
  Neoplasm, 205
Charged particle irradiation, 755
Chemosensitivity (5-fluorouracil), Intrinsic, 511
Chemotherapy, 49, 79, 593, 633, 737
Chest wall, 261
Children, 79
Chromatin fragments, 139
Chromosome aberrations, 279, 737
Cisplatin, 295
Clonogenic assay with high plaing efficiency, 511
CNPase, 929
CNS
  Prophylaxis, 49
  Tolerance, 133
  Tumors, 619
Collateral resistance, 527
Colon cancer, 329
Combined modality therapy, 17, 633
Combined tumor therapy, 699
Complications, 145, 261, 315
  Late, 217
Conformal radiation therapy, 485
Conservative treatment, 469
Continuous, 87
Control
  Local, 145
  Tumor, 261
Craniopharyngioma, Pediatric, 611
Cryptorchidism, 153
CSF, 929
Cyclophosphamide, 295

D

Demyelination, 929
Development, 505
Differentiation, 451
Disease
  Extramammary Paget's, 73
  Hodgkin's, 737
  Microscopic, 261
Dissection, Groin, 389
Distant metastases(is), 197, 423
DNA
  Repair, 939
  Supercoiling, 713
Dose
  Calculation, 789
  Total, 65
Dose-rate, 965
  Effects, 699
Dosimetric analysis, 651
Dosimetry, 127, 329, 789, 795
  Radiation, 559
  Thermoluminescent, 559
DU-145, 519
Dysgerminoma, 161

E

Education, 819, 837
Effect(s)
  Dose rate, 699
  Late, 505
  Side, 497
  Tumor bed, 111
Endometrial
  Cancer, 223
  Carcinoma, 229
Episcleral radiotherapy, 247
Epithelial cells, 533
Esophageal cancer, 633

External beam
Fractionated, 111
Radiotherapy, 729
External radiation therapy, 59
Extramammary Paget's disease, 73

F

Facility survey, 983
Factor(s)
Growth, 93
Lung correction, 789
Nuclear roundness, 431
Prognostic, 145, 161, 211
Failure
Local, 431
Pelvic, 423
Fanconi's anemia, 949
Fast neutrons, 975
Fibroblasts, 287
5-fluorouracil, 519
Flow cytometry, 87
Fluorescence *in situ* hybridization, 279, 737
Fractionated external beam, 111
Fractionation, 217, 335, 505
Accelerated, 497
Function
Motor, 627
Pulmonary, 31
Sphincter, 627
Functional outcome, 651

G

Gastric cancer, 729
Gene therapy, 565
Glioblastoma, 583
Multiforme, 593
Glioma(s), 111, 583, 657
Brainstem, 599
Malignant, 55, 675
Glutathione (GSH), 103, 527
Groin
Dissection, 389
Radiation, 389
Growth factors, 93

H

Head and neck, 87
Cancer(s), 59, 359
Heart irradiation, 721
Heat shock, 543
HeLa, 519
Hemothorax irradiation, 643
Heterogeneity corrections, 789
High-dose rate, 349
Afterloaders, 167
Afterloading, 335
Brachytherapy, 795
Hodgkin's disease, 737
Hospital information systems, 369
HT-29, 519
Human tumor(s), 511
Cells, 119
Ovarian, 527
Xenografts, 669
Hybrid spheroids, 511
Hyperfractionated
Accelerated radiotherapy, 87
Irradiation, 681
Hyperfractionation, 43, 599
Hyperthermia, 145, 261, 489, 543, 657, 669, 965
Hypofractionation, 761
Hypoxic
Cell radiosensitizer, 959
Fraction, 295

I

^{131}I, 127
Implants, 321
Iridium, 479
Incidental prostate cancer, 415
Interstitial, 555
Brachytherapy, 479, 583
Irradiation, 657
Intracavitary, 335, 349
Brachytherapy, 235
Intraoperative
Radiation therapy, 949
Radiotherapy, 559, 729
Intratumoral injection, 959
Intrinsic
Chemosensitivity (5-fluorouracil), 511
Radiosensitivity, 511
^{131}Iodine monoclonal antibodies, 329
Iodine-125, 555, 583
Ionizing radiation, 687, 949
Iridium, 59
Implant, 479
Iridium-192, 167, 469
Irradiation, 197, 223
Charged particle, 755
Heart, 721
Hemothorax, 643
Hyperfractionated, 681
Interstitial, 657
Photon, 527
Prophylactic cranial, 43
Total body, 139, 789
Whole body, 139

K

Keratinocytes, 287, 533

L

Lacrimal gland, 693
Laminectomy, 627
Laryngeal cancer, 497
Late
Complications, 217
Effects, 505
Limited stage small cell lung cancer, 43
Linear-quadratic, 335
Local
Control, 145
Failure, 431
Recurrence, 253
Locally advanced gastric adenocarcinoma, 921
Locoregional relapse, 241
Long term results, 611
Low-dose rate, 335, 349
Lumpectomy, 253
Lung
Correction factor, 789
Neoplasm(s), 3, 25, 31
Non-small cell carcinoma, 17, 37
Lung cancer
Limited stage small cell, 43
Non-small cell, 11, 551
Lymphogram, 223

M

Magnetic resonance imaging, 767
Malignant glioma(s), 55, 675
MBP, 929
Medical records, 369
Medulloblastoma, 79
Mesothelioma, 643
Metastase(is)
Brain, 619
Distant, 197, 423
Para-aortic nodal, 229
Metastatic
Cord compression, 301
Spinal cord compression, 627
Micro-computers, 369
Microdosimetry, 975
Microscopic disease, 261
Mitomycin C, 295
Mitoxantrone, 669
Models, 699
Monoclonal antibodies, 127, 329
^{131}Iodine, 329
Motor function, 627
Moving source, 795
MTT assay, 675
Multi-leaf collimator, 781
Multicellular spheroids, 119
Multimodality therapy, 643
Multivariate analysis, 205
Myelopathy, 929
Radiation, 133, 505

N

Necrosis, 593
Neonatal thymectomy, 133
Neoplasm(s)
Lung, 3, 25, 31
Brain, 103, 583, 767
Cervix, 205
Neurotoxicity, 49
Non-small cell, 3
Lung cancer, 11, 551
Lung carcinoma, 17, 37
Norepinephrine, 721
Nuclear roundness factor, 431
Nucleoid, 713
Number of treatments, 145

O

192 brachytherapy, 59
Optic nerve injury, 307
Oral sequelae, 359
Orthovoltage, 171
Osteosarcoma, 761
Ovarian cancer, 161

P

Pain relief, 627
Para-aortic
Nodal metastasis, 229
Nodes, 223
Pattern(s) of
Recurrence, 423

Care, 913
Failure, 17, 633
Pediatric
Brain tumors, 599
Craniopharyngioma, 611
Pelvic failure, 423
Penile carcinoma, 479
Perfusion scan, 31
Pharmacokinetics, 949
Photon irradiation, 527
Pituitary
Adenoma, 307
Carcinoma, 307
PLD repair, 533
Post-treatment biopsy, 403
Precision radiotherapy, 781
Predictive assays, 279
Preventive regimens, 359
Primary culture, 287
Primary resection, 921
Prognostic
Factors, 145, 161, 211, 261
Variables, 423
Programmed cell death, 693
Prophylactic cranial irradiation, 43
Prophylaxis, CNS, 49
Prostate, 409, 555
Carcinoma, 431
Prostate cancer, 403, 423, 435, 485, 489
Blacks and, 441
Race and, 441
Prostatic carcinoma, 451
Protein kinase C, 687
Pterygium, 315
Pulmonary
Fibrosis, 93
Function, 31

Q

Quality assurance, 777
Radiotherapy, 559
Quality of life, 301

R

Race and prostate cancer, 441
Radiation, 253, 287, 307, 409, 737, 913, 929
Dosimetry, 559
Groin, 389
Ionizing, 687, 949
Myelitis, 681
Myelopathy, 133, 505
Quality, 975
Stereotactic, 619
Surgery and, 611
Thoracic, 43
Radiation oncology, 819
Equipment, 983
Personnel, 983
Radiation therapy, 3, 31, 37, 103, 229, 301, 403, 423, 489, 583, 627, 747
Adjuvant, 463
Conformal, 485
External, 59
Intraoperative, 949
Radiation tolerance, 505
Of spinal cord, 681
Radioimmunotherapy, 111, 127, 329
Radiolabeled antibodies, 329
Radioprotection, 713
Radioprotector, 139
Radioresistant human melanoma (U1-Mel) cells, 939
Radiosensitivity, 119, 279, 533, 675
Cellular, 699
Intrinsic, 511
Modulation, 519
Radiosensitizer, 11
Hypoxic cell, 949
Radiosurgery, 619, 777
Radiotherapy, 11, 25, 49, 55, 65, 73, 79, 205, 211, 235, 241, 321, 359, 415, 431, 435, 599, 633, 761, 777, 819, 837
Episcleral, 247
External beam, 729
Hyperfractionated accelerated, 87
Intraoperative, 559, 729
Precision, 781
Quality assurance, 559
^{186}Re, 127
Receptor
α-adrenergic, 721
β-adrenergic, 721
Rectal carcinoma, 241
Recurrence(s), 55, 551
Local, 253
Recurrent breast cancer, 261
Reentrant ionization chambers, 167
Reirradiation, 261, 307
Remote afterloading, 321
Reoxygenation, 295
Repair, 335
DNA, 939
PLD, 533
SLD, 533
Sublethal damage, 119
Repopulation, 533
RIF-1, 295
RK-28, 959

S

Sarcoma therapy, 651
Second cancers, 913
Second malignant tumors, 59
Seminal vesicles, 435
Seminoma, 153, 913
Serum-free culture, 533
Short treatment time, 65
Side effects, 497
Skin reaction, 533
SLD repair, 533
Smoking, 451
SOS response, 949
Sphincter function, 627
Spinal cord, 505
Radiation tolerance, 681
Squamous cell carcinomas, 59
Stage III, 17
Stage IIIA, 211
Stem cells, 119
Stereotactic radiation, 619
Stereotaxy, 781
Sublethal-damage, 965
Repair, 119
Superficial lesions, 145
Surgery, 25
And radiation, 611
Survival, 451

T

TDF values, 217
Temporal lobe necrosis, 307
Therapy, 329
Adjuvant, 921
Cancer, 329
Combined modality, 633
Combined tumor, 699
Conformal radiation, 485
Gene, 565
Multimodality, 643
Radiation, 3, 31, 37, 103, 229, 301, 403, 423, 489, 583, 627, 747
Sarcoma, 651
Thermal
Parameters, 261
Radiosensitization, 543
Thermoluminescent dosimetry, 559
Thermotolerance, 543
Thoracic
Esophageal carcinoma, 235
Radiation, 43
Three-dimensional
Radiotherapy treatment planning, 767
Treatment planning, 781
Tissue-type plasminogen activator, 949
Tolerance
CNS, 133
Radiation, 505
Topoisomerase I, 939
Total body irradiation, 139, 789
Total dose, 65
Toxicity, 65
Bowel, 463
Transcription, 565
Translocations, 737
Treatment planning, 975
Three-dimensional 781
Three-dimensional radiotherapy, 767
Treatment, 161
Conservative, 469
Tumor(s)
Bed effect, 111
Bone, 755
Brain, 79
CNS, 619
Combined therapy, 699
Control, 261
Human, 511
Human ovarian, 527
Pediatric brain, 599
Response evaluation, 643
Second malignant, 59

U

Uveal melanoma, 247

V

Vagina, 747
Volume-dose, 555
V-79, 519

W

Whole body irradiation, 139
WiDr, 519
WR1065, 713

X

X-ray(s), 565
Ssynergism, 939
Xenograft(s), 111, 119
Human tumor, 669
Xerophthalmia, 693

Y

Yttrium-90, 111